Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
We haven't written up this one. MarketWatch has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company statnews.com
- Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug endpoints.news
- Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff marketwatch.com
- Pharma major Novartis falls nearly 10%, heading for worst day on record after three drug trial setbacks cnbc.com
